NasdaqGS - Delayed Quote • USD
Vaxcyte, Inc. (PCVX)
At close: May 9 at 4:00 PM EDT
After hours: May 9 at 4:02 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 8 |
| Avg. Estimate | -1.17 | -1.14 | -4.28 | -4.48 |
| Low Estimate | -1.72 | -1.74 | -4.75 | -5.59 |
| High Estimate | -0.84 | -0.9 | -3.74 | -3.02 |
| Year Ago EPS | -0.7 | -0.7 | -4.14 | -4.28 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 8 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.83 | -0.74 | -0.84 | -1.07 |
| EPS Actual | -0.7 | -0.7 | -0.91 | -1.82 |
| Difference | 0.13 | 0.04 | -0.07 | -0.75 |
| Surprise % | 15.70% | 5.40% | -8.30% | -70.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.17 | -1.14 | -4.28 | -4.48 |
| 7 Days Ago | -1.17 | -1.15 | -4.31 | -4.48 |
| 30 Days Ago | -1.17 | -1.15 | -4.31 | -4.48 |
| 60 Days Ago | -1.09 | -1.07 | -4.31 | -4.48 |
| 90 Days Ago | -1.06 | -1.15 | -4.28 | -4.4 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | -- |
| Up Last 30 Days | -- | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PCVX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -67.10% | -- | -- | 8.60% |
| Next Qtr. | -62.90% | -- | -- | 11.90% |
| Current Year | -3.40% | -- | -- | 5.60% |
| Next Year | -4.70% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -31.80% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 5/9/2024 |
| Reiterates | Needham: Buy to Buy | 5/9/2024 |
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Maintains | Mizuho: Buy to Buy | 3/12/2024 |
| Maintains | Needham: Buy to Buy | 2/28/2024 |
| Maintains | B of A Securities: Buy to Buy | 1/2/2024 |
Related Tickers
NUVL Nuvalent, Inc.
67.52
-0.03%
ITOS iTeos Therapeutics, Inc.
12.19
-0.08%
LEGN Legend Biotech Corporation
45.52
-0.44%
ASND Ascendis Pharma A/S
133.13
-0.60%
RVMD Revolution Medicines, Inc.
37.45
-2.24%
IDYA IDEAYA Biosciences, Inc.
40.64
-1.86%
KYMR Kymera Therapeutics, Inc.
38.61
+0.29%
ACLX Arcellx, Inc.
52.73
+0.92%
RLAY Relay Therapeutics, Inc.
6.31
-3.07%
IMVT Immunovant, Inc.
29.70
-0.20%